Novartis and Idenix Pursue Interdependent Growth
Executive Summary
Novartis has capped a recent dealmaking spree with its most innovative deal yet--a half-acquisition of, half-alliance with, Idenix Pharmaceuticals. The big Swiss company agreed to pay $255 million to acquire a 51% equity stake in the private biotech company.
You may also be interested in...
Vertex/J&J: Pushing Big Pharma's Deal Flexibility to the Limit
Vertex Pharmaceuticals deal with Johnson & Johnson for its Phase II hepatitis C protease inhibitor VX-950 underscore the significant potential for HCV protease inhibitors to alter the landscape of disease treatment and suggests pharmaceutical dealmakers will have to be ever more flexible to land biotech's best products.
Vertex/J&J: Pushing Big Pharma's Deal Flexibility to the Limit
Vertex Pharmaceuticals deal with Johnson & Johnson for its Phase II hepatitis C protease inhibitor VX-950 underscore the significant potential for HCV protease inhibitors to alter the landscape of disease treatment and suggests pharmaceutical dealmakers will have to be ever more flexible to land biotech's best products.
Hep C Development Dilemma: Big Money Now or Bigger Money Later?
As Big Pharma finds itself searching for products in smaller, more specialist markets, biotechs must decide whether it is better to take a product to market alone and reap the rewards while dealing with the risks, or take the money and run. Such is the happy dilemma for biotechs developing new drugs for HCV, an exploding market blessed with quick development timeframes and early proof-of-concept potential.